



MEN

**FIRST CANCER SITE  
ORAL CAVITY**
**ORAL CAVITY  
POOL AIRTUM 1976-2010, MEN:**

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

**CAVITÀ ORALE  
POOL AIRTUM 1976-2010, UOMINI:**

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
	No. of subjects alive at interval beginning ▶	Person-years ▶	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
<b>SECOND CANCER SITE</b>	<b>0</b>	<b>SIR</b>	<b>0</b>	<b>SIR</b>	<b>0</b>	<b>SIR</b>	<b>0</b>	<b>SIR</b>	<b>0</b>	<b>SIR</b>	<b>0</b>	<b>SIR</b>	<b>0</b>	<b>SIR</b>	<b>EAR</b>	<b>EAR</b>
<b>ALL SITES, BUT SKIN AND ORAL CAVITY</b>	1151	<b>1.93</b>	1406	<b>2.25</b>	255	<b>9.47</b>	172	<b>1.57</b>	572	<b>2.14</b>	291	<b>1.97</b>	116	<b>1.62</b>	<b>16.03</b>	<b>21.54</b>
HEAD AND NECK	174	<b>6.17</b>	261	<b>8.82</b>	87	<b>62.26</b>	29	<b>5.08</b>	92	<b>6.92</b>	42	<b>6.48</b>	11	<b>4.04</b>	<b>4.21</b>	<b>6.37</b>
ORAL CAVITY	36	<b>5.38</b>	47	<b>6.69</b>	11	<b>33.34</b>	6	<b>4.45</b>	15	<b>4.77</b>	11	<b>7.11</b>	4	<b>6.13</b>	<b>0.85</b>	<b>1.10</b>
PHARYNX	65	<b>10.32</b>	78	<b>11.80</b>	13	<b>41.80</b>	13	<b>10.17</b>	36	<b>12.02</b>	11	<b>7.63</b>	5	<b>8.59</b>	<b>1.70</b>	<b>1.97</b>
LARYNX	73	<b>4.80</b>	136	<b>8.52</b>	63	<b>83.29</b>	10	<b>3.24</b>	41	<b>5.73</b>	20	<b>5.73</b>	2	<b>1.35</b>	<b>1.67</b>	<b>3.30</b>
OESOPHAGUS	113	<b>16.30</b>	146	<b>20.10</b>	33	<b>99.43</b>	18	<b>13.33</b>	58	<b>18.08</b>	28	<b>17.01</b>	9	<b>12.36</b>	<b>3.07</b>	<b>3.82</b>
STOMACH	49	<b>1.38</b>	55	<b>1.48</b>	6	<b>3.50</b>	8	1.17	28	<b>1.75</b>	8	0.93	5	1.23	0.39	0.49
COLON RECTUM	86	1.06	91	1.08	5	1.39	14	0.96	41	1.14	21	1.03	10	1.00	0.15	0.18
COLON	55	1.00	57	0.99	2	0.83	10	1.02	21	0.86	16	1.15	8	1.15	0.00	-0.02
RECTUM	31	1.20	34	1.26	3	2.55	4	0.84	20	<b>1.73</b>	5	0.79	2	0.65	0.15	0.19
LIVER	51	<b>2.09</b>	58	<b>2.27</b>	7	<b>6.34</b>	6	1.33	22	<b>1.99</b>	13	<b>2.16</b>	10	<b>3.49</b>	<b>0.77</b>	<b>0.89</b>
GALLBLADDER	8	1.32	8	1.26	0	0.00	2	1.81	5	1.87	1	0.66	0	0.00	0.06	0.05
PANCREAS	22	1.36	22	1.30	0	0.00	8	<b>2.71</b>	10	1.39	3	0.75	1	0.51	0.17	0.14
LUNG	339	<b>3.16</b>	423	<b>3.76</b>	84	<b>16.69</b>	47	<b>2.30</b>	184	<b>3.76</b>	84	<b>3.24</b>	24	<b>1.97</b>	<b>6.70</b>	<b>8.55</b>
SKIN MELANOMA	8	0.89	8	0.85	0	0.00	3	1.84	1	0.25	4	1.79	0	0.00	-0.03	-0.04
MESOTHELIOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.09	-0.09
KAPOSI SARCOMA	1	0.79	2	1.51	1	16.73	0	0.00	1	1.74	0	0.00	0	0.00	-0.01	0.02
SOFT TISSUE	3	1.41	3	1.35	0	0.00	0	0.00	2	2.08	0	0.00	1	4.02	0.03	0.02
BONE	2	3.52	3	<b>5.03</b>	1	35.42	0	0.00	2	7.63	0	0.00	0	0.00	0.04	0.07
BREAST	1	0.77	1	0.74	0	0.00	0	0.00	1	1.72	0	0.00	0	0.00	-0.01	-0.01
PROSTATE	97	0.85	103	0.87	6	1.28	8	<b>0.42</b>	41	0.83	32	1.07	16	1.05	-0.49	-0.43
TESTIS	1	1.14	1	1.08	0	0.00	0	0.00	1	2.35	0	0.00	0	0.00	0.00	0.00
KIDNEY AND RENAL PELVIS	24	1.23	26	1.28	2	2.28	3	0.84	11	1.24	6	1.25	4	1.78	0.13	0.15
BLADDER AND URINARY TRACT	102	<b>1.55</b>	109	<b>1.59</b>	7	2.34	13	1.07	38	1.29	36	<b>2.22</b>	15	<b>1.89</b>	<b>1.05</b>	<b>1.11</b>
URINARY BLADDER	99	<b>1.58</b>	103	<b>1.57</b>	4	1.40	12	1.03	38	1.35	34	<b>2.19</b>	15	<b>1.98</b>	<b>1.05</b>	<b>1.03</b>
URINARY TRACT	3	1.06	6	2.04	3	<b>23.48</b>	1	1.94	0	0.00	2	2.86	0	0.00	0.01	0.08
BRAIN AND CENTRAL NERVOUS SYSTEM	4	0.55	5	0.66	1	2.93	0	0.00	3	0.90	0	0.00	1	1.26	-0.09	-0.07
THYROID	9	<b>2.94</b>	16	<b>5.00</b>	7	<b>50.51</b>	4	<b>6.96</b>	4	2.83	0	0.00	1	3.06	0.17	<b>0.35</b>
HODGKIN LYMPHOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.04	-0.04
NON-HODGKIN LYMPHOMA	26	1.49	30	<b>1.65</b>	4	<b>5.07</b>	5	1.55	13	1.65	6	1.40	2	0.99	0.25	0.33
MYELOMA	6	0.78	6	0.74	0	0.00	0	0.00	2	0.58	2	1.04	2	2.15	-0.05	-0.06
LEUKAEMIAS	18	1.34	20	1.43	2	3.21	5	1.99	6	1.00	6	1.83	1	0.63	0.13	0.16
LYMPHOID LEUKAEMIAS	3	0.46	5	0.73	2	6.54	1	0.81	1	0.34	1	0.63	0	0.00	-0.10	-0.05
MYELOID LEUKAEMIAS	15	<b>2.52</b>	15	<b>2.41</b>	0	0.00	4	3.64	5	1.89	5	<b>3.39</b>	1	1.36	<b>0.26</b>	0.24
OTHER LEUKAEMIAS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
OTHER AND ILL DEFINED SITES	43	<b>1.43</b>	56	<b>1.78</b>	13	<b>9.42</b>	5	0.90	21	1.57	10	1.35	7	1.90	<b>0.37</b>	<b>0.68</b>

Decrease/Difetto  
Increase/Eccesso

O Observed cases  
Casi osservati

SIR Standardized Incidence Ratio  
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk  
Eccesso assoluto di rischio



WOMEN

**FIRST CANCER SITE  
ORAL CAVITY**

**ORAL CAVITY  
POOL AIRTUM 1976-2010, WOMEN:**  
Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

**CAVITÀ ORALE  
POOL AIRTUM 1976-2010, DONNE:**  
Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
	No. of subjects alive at interval beginning ▶	4608	4899		4899		4608		3312		1306		459		4608	4899
Person-years ▶	17303	18096		792		3275		8097		4132		1799		17303	18096	
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT SKIN AND ORAL CAVITY	286	1.48	331	1.64	45	5.18	51	1.45	142	1.62	67	1.41	26	1.17	5.40	7.17
HEAD AND NECK	49	19.85	58	22.47	9	80.39	5	11.00	21	18.62	18	29.76	5	17.75	2.69	3.06
ORAL CAVITY	29	21.51	33	23.41	4	65.10	3	12.17	10	16.45	13	38.97	3	18.74	1.60	1.75
PHARYNX	11	20.70	11	19.80	0	0.00	0	0.00	6	24.29	4	31.19	1	17.61	0.61	0.58
LARYNX	9	15.26	14	22.72	5	189.61	2	18.37	5	18.32	1	6.99	1	15.43	0.49	0.74
OESOPHAGUS	23	23.67	29	28.53	6	133.59	1	5.61	15	34.36	7	29.10	0	0.00	1.27	1.55
STOMACH	6	0.51	7	0.57	1	1.77	1	0.45	2	0.38	3	1.04	0	0.00	-0.33	-0.30
COLON RECTUM	30	0.99	31	0.98	1	0.73	3	0.55	16	1.18	8	1.06	3	0.84	-0.01	-0.03
COLON	18	0.83	19	0.84	1	1.02	2	0.51	7	0.72	7	1.29	2	0.77	-0.21	-0.20
RECTUM	12	1.42	12	1.36	0	0.00	1	0.65	9	2.35	1	0.48	1	1.03	0.21	0.18
LIVER	3	0.58	3	0.55	0	0.00	1	1.05	2	0.85	0	0.00	0	0.00	-0.13	-0.14
GALLBLADDER	3	0.71	3	0.68	0	0.00	1	1.27	1	0.53	1	0.96	0	0.00	-0.07	-0.08
PANCREAS	5	0.63	5	0.60	0	0.00	2	1.41	2	0.57	1	0.50	0	0.00	-0.17	-0.18
LUNG	57	4.70	66	5.21	9	17.02	8	3.72	34	6.22	12	3.93	3	2.05	2.59	2.95
SKIN MELANOMA	2	0.57	3	0.82	1	6.58	0	0.00	2	1.25	0	0.00	0	0.00	-0.09	-0.04
MESOTHELIOMA	1	1.97	1	1.89	0	0.00	0	0.00	1	4.36	0	0.00	0	0.00	0.03	0.03
KAPOSI SARCOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.02
SOFT TISSUE	6	7.55	6	7.23	0	0.00	1	6.92	4	11.06	0	0.00	1	10.85	0.30	0.29
BONE	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.01	-0.01
BREAST	60	1.24	70	1.39	10	4.65	16	1.80	24	1.08	15	1.27	5	0.93	0.68	1.08
CERVIX UTERI	4	1.62	5	1.93	1	8.45	0	0.00	2	1.71	1	1.74	1	4.17	0.09	0.13
CORPUS UTERI	12	1.39	12	1.33	0	0.00	2	1.26	1	0.25	4	1.91	5	5.34	0.20	0.17
OVARY	3	0.50	4	0.64	1	3.70	1	0.90	1	0.36	1	0.69	0	0.00	-0.17	-0.12
KIDNEY AND RENAL PELVIS	5	1.09	6	1.25	1	5.01	0	0.00	4	1.93	1	0.87	0	0.00	0.02	0.07
BLADDER AND URINARY TRACT	4	0.54	4	0.52	0	0.00	0	0.00	3	0.90	1	0.54	0	0.00	-0.20	-0.21
URINARY BLADDER	4	0.58	4	0.56	0	0.00	0	0.00	3	0.97	1	0.58	0	0.00	-0.17	-0.18
URINARY TRACT	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
BRAIN AND CENTRAL NERVOUS SYSTEM	1	0.37	2	0.70	1	8.22	1	2.01	0	0.00	0	0.00	0	0.00	-0.10	-0.05
THYROID	5	1.47	9	2.53	4	27.33	4	6.46	1	0.63	0	0.00	0	0.00	0.09	0.30
HODGKIN LYMPHOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
NON-HODGKIN LYMPHOMA	13	1.83	14	1.88	1	3.16	3	2.33	5	1.54	4	2.27	1	1.22	0.34	0.36
MYELOMA	4	1.19	4	1.14	0	0.00	1	1.64	1	0.66	0	0.00	2	5.10	0.04	0.03
LEUKAEMIAS	4	0.83	4	0.79	0	0.00	0	0.00	2	0.92	2	1.68	0	0.00	-0.05	-0.06
LYMPHOID LEUKAEMIAS	1	0.47	1	0.45	0	0.00	0	0.00	1	1.04	0	0.00	0	0.00	-0.07	-0.07
MYELOID LEUKAEMIAS	3	1.32	3	1.27	0	0.00	0	0.00	1	0.98	2	3.54	0	0.00	0.04	0.03
OTHER LEUKAEMIAS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.02
OTHER AND ILL DEFINED SITES	15	1.03	18	1.18	3	4.45	3	1.13	8	1.23	1	0.27	3	1.67	0.02	0.15

Decrease/Difetto  
Increase/Eccesso

O Observed cases  
Casi osservati

SIR Standardized Incidence Ratio  
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk  
Eccesso assoluto di rischio